Eatontown, NJ – (GlobeNewswire) – March 14, 2013 – American CryoStem Corporation (OTCQB: CRYO), a leading biotech company in the field of Regenerative Medicine, today announced that it has named Hanover|Elite as the Company’s Investor and Public Relations counsel of record.
Hanover|Elite is a joint venture created through the partnership of Hanover International, Inc. and Elite Financial Communications Group. Hanover and Elite have teamed to leverage their respective strengths, resources and spheres of influence on Wall Street creating an innovative IR/PR model for applying best industry practices in financial communications, corporate branding and awareness, regulatory compliance and capital market access services.
In collaboration with American CryoStem’s senior leadership, Hanover|Elite is charged with developing, implementing and supporting a fully integrated corporate and shareholder communications platform for the Company; generating meaningful awareness among and measurable support from the retail and institutional investment communities; and assisting management on the formulation, refinement and execution of its short- and long-term capital access strategies. Jim Hock, CEO of Hanover and JV Managing Partner, along with Dodi Handy, CEO of Elite and JV Managing Partner, will lead the combined IR/PR teams providing strategic counsel and direction.
“American CryoStem appears to have reached a critical inflexion point in its development and is well poised to distinguish itself as a pioneering force in the emerging fields of Personalized and Regenerative Medicine,” stated Hock. “Consequently, Hanover|Elite is very proud to be teaming with the Company to help ensure that investors, investment professionals, industry stakeholders and consumers, alike, come to know, appreciate and support American CryoStem as it moves into what is anticipated to be a highly dynamic phase of global growth and differentiation.”
About American CryoStem Corporation
American CryoStem Corporation is a leading biotech company focused on marketing its clinical processing services and patented products for adipose (fat) tissue and adipose derived adult stem cells. Its clinical tissue processing, patented cell culture media products and tissue storage platform supports cosmetic and regenerative medicine applications currently being developed globally. The Company provides high quality, clinically processed viable cells, while at the same time is developing cutting edge applications, therapies, patented laboratory products and services for consumer and commercial applications. For more information, visit www.americancryostem.com.
Cautionary Statement Regarding Forward Looking Information
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “may”, “should”, variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product potential or financial performance. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect the business of American CryoStem Corp. and its markets, particularly those discussed in the risk factors and cautionary statements in filings made by the Company with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and the Company assumes any responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Jim Hock or Dodi Handy